Press Release: FDA Approves New Bladder Cancer Treatment

May 18, 2016
by Andrea Maddox-Smith

The Bladder Cancer Advocacy Network (BCAN) applauds the U.S. Food and Drug Administration (FDA) approval of an innovative, first-of-its-kind bladder cancer treatment, establishing a brand new class of therapy for the disease. Genentech, a member of the Roche Group, produced this new treatment, TECENTRIQ™ (atezolizumab), which allows the body’s immune system to work more effectively to fight cancer.

Read More...

BCAN at ASCO GU

January 11, 2016
by Stephanie Chisolm

BCAN just returned from the American Society of Clinical Oncology’s 2016 Genitourinary Cancer Symposium held January 7-9 in San Francisco.

Read More...

2015: A Moment of Reflection

December 22, 2015
by Diane Quale

As we reflect back on 2015–BCAN’s 10th anniversary year–we should all be very proud of what we have accomplished. We have created a vibrant community of survivors, co-survivors, family, friends, and medical professionals who are giving bladder cancer a voice and improving the lives of all who are impacted by this disease.

Read More...

Did you know October 15 – December 7 is Medicare Open Enrollment for 2016 Coverage?

October 15, 2015
by Stephanie Chisolm

Medicare is a health insurance program for: people age 65 or older, people under age 65 with certain disabilities, and people of all ages with End-Stage Renal Disease (permanent kidney failure requiring dialysis or a kidney transplant). Your health needs may change from one year to the next. Your health plan may also change its benefits and costs each year too. Medicare Open Enrollment (October 15–December 7) is the time when all people with Medicare are encouraged to review their current health and prescription drug coverage. This review includes checking on any changes in costs, coverage, and benefits that will…

Read More...

Press Release – BCAN Launches Bladder Cancer Genomics Consortium

September 24, 2015
by Monica Smith

The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. This prospective study is the first project of the Bladder Cancer Genomics Consortium (BCGC), a collaborative effort between BCAN and major medical centers.

Read More...

BCAN Joins the Rally for Research

September 14, 2015
by Stephanie Chisolm

The next few years are a time of great promise in medical research for the diagnosis and treatment of bladder cancer. The National Institutes of Health (NIH), a part of the Department of Health and Human Services, is the nation’s medical research agency.

Read More...

A Commitment to Quality Programs

August 21, 2015
by Monica Smith

Through the generous support of Amgen and the University of California at Berkeley Haas School of Business, we have the opportunity to transform our Patient Insight Webinar Series.

Read More...